SYRE
Spyre Therapeutics, Inc. NASDAQ Listed Apr 7, 2016$73.10
Mkt Cap $4.4B
52w Low $12.29
95.4% of range
52w High $76.00
50d MA $53.83
200d MA $32.05
P/E (TTM)
-35.1x
EV/EBITDA
-53.7x
P/B
33.6x
Debt/Equity
0.0x
ROE
-21.7%
P/FCF
-67.0x
RSI (14)
—
ATR (14)
—
Beta
2.94
50d MA
$53.83
200d MA
$32.05
Avg Volume
977.0K
Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.
221 Crescent Street · Waltham, MA 02453 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 19, 2026 | BMO | -0.66 | -0.70 | -6.1% | 37.81 | +0.0% | +14.3% | +14.3% | +16.8% | +14.9% | +16.1% | — |
| Nov 4, 2025 | BMO | -0.68 | -0.15 | +77.9% | 22.98 | +1.7% | -0.6% | -0.6% | -2.6% | -2.0% | -3.5% | — |
| Aug 5, 2025 | BMO | -0.73 | -0.49 | +32.9% | 16.87 | +0.1% | -5.4% | -5.4% | -9.7% | -10.1% | -9.6% | — |
| May 8, 2025 | BMO | -0.76 | -0.74 | +2.6% | 12.86 | +5.3% | +9.6% | +9.6% | +16.1% | +14.7% | +15.1% | — |
| Feb 27, 2025 | BMO | -0.89 | -0.81 | +9.0% | 18.37 | +1.7% | +7.2% | +7.2% | -2.3% | -0.8% | +6.0% | — |
| Nov 7, 2024 | BMO | -0.80 | -1.36 | -70.0% | 37.69 | -4.8% | +5.0% | +5.0% | +4.4% | -5.0% | -12.5% | — |
| Aug 7, 2024 | BMO | -0.90 | -0.86 | +4.4% | 24.55 | +3.6% | +2.9% | +2.9% | +1.0% | -1.0% | +3.0% | — |
| May 9, 2024 | BMO | -0.90 | -1.20 | -33.3% | 35.19 | +9.8% | +4.9% | +4.9% | +5.1% | +11.7% | +6.2% | — |
| Feb 29, 2024 | BMO | -0.48 | -2.28 | -375.0% | 27.44 | +10.0% | +9.0% | +9.0% | +27.4% | +37.2% | +46.7% | — |
| Nov 9, 2023 | BMO | -0.84 | -9.34 | -1011.9% | 9.47 | -2.5% | +0.2% | +0.2% | +7.5% | +13.5% | +14.1% | — |
| Aug 11, 2023 | BMO | -4.50 | -1.66 | +63.1% | 12.50 | -4.0% | -5.8% | -5.8% | -6.4% | -7.6% | -4.6% | — |
| Mar 31, 2023 | BMO | -4.50 | -4.89 | -8.6% | 7.25 | +2.5% | -1.7% | -1.7% | -4.4% | -9.2% | -10.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 17 | Jones Trading | Maintains | Buy → Buy | — | $69.70 | $70.32 | +0.9% | +4.7% | +5.3% | +2.3% | +4.7% | -0.7% |
| Apr 14 | Baird | Maintains | Outperform → Outperform | — | $63.27 | $67.68 | +7.0% | +1.2% | +9.0% | +10.2% | +15.4% | +16.0% |
| Apr 14 | Wells Fargo | Maintains | Overweight → Overweight | — | $63.27 | $67.68 | +7.0% | +1.2% | +9.0% | +10.2% | +15.4% | +16.0% |
| Apr 14 | Wedbush | Maintains | Outperform → Outperform | — | $63.27 | $67.68 | +7.0% | +1.2% | +9.0% | +10.2% | +15.4% | +16.0% |
| Apr 14 | Deutsche Bank | Maintains | Buy → Buy | — | $63.27 | $67.68 | +7.0% | +1.2% | +9.0% | +10.2% | +15.4% | +16.0% |
| Apr 13 | BTIG | Maintains | Buy → Buy | — | $51.29 | $67.00 | +30.6% | +23.4% | +24.8% | +34.5% | +35.9% | +42.3% |
| Apr 13 | Leerink Partners | Maintains | Outperform → Outperform | — | $51.29 | $67.00 | +30.6% | +23.4% | +24.8% | +34.5% | +35.9% | +42.3% |
| Apr 13 | Jefferies | Maintains | Buy → Buy | — | $51.29 | $67.00 | +30.6% | +23.4% | +24.8% | +34.5% | +35.9% | +42.3% |
| Mar 31 | BTIG | Maintains | Buy → Buy | — | $45.42 | $46.28 | +1.9% | +11.1% | +7.7% | +4.8% | +7.8% | +12.7% |
| Mar 18 | Stifel | Maintains | Buy → Buy | — | $43.95 | $44.28 | +0.8% | -2.0% | -3.7% | -6.1% | -2.7% | -3.9% |
| Mar 16 | BTIG | Maintains | Buy → Buy | — | $39.89 | $40.73 | +2.1% | +10.5% | +10.2% | +7.9% | +6.1% | +3.4% |
| Feb 20 | BTIG | Maintains | Buy → Buy | — | $37.81 | $37.82 | +0.0% | +14.3% | +16.8% | +14.9% | +16.1% | +14.1% |
| Feb 20 | Wells Fargo | Maintains | Overweight → Overweight | — | $37.81 | $37.82 | +0.0% | +14.3% | +16.8% | +14.9% | +16.1% | +14.1% |
| Jan 16 | BTIG | Maintains | Buy → Buy | — | $33.09 | $33.20 | +0.3% | +0.5% | +1.9% | +2.7% | +3.0% | -3.2% |
| Dec 1 | Jones Trading | Upgrade | Hold → Buy | — | $30.00 | $30.55 | +1.8% | -4.5% | -5.3% | +7.3% | +11.7% | +11.5% |
| Sep 16 | BTIG | Maintains | Buy → Buy | — | $14.84 | $14.84 | +0.0% | -0.1% | +1.4% | +3.2% | +0.3% | +3.0% |
| Nov 13 | Baird | Maintains | Outperform → Outperform | — | $35.82 | $36.39 | +1.6% | -7.9% | -12.7% | -18.5% | -20.0% | -24.9% |
| Oct 25 | Guggenheim | Maintains | Buy → Buy | — | $33.70 | $34.94 | +3.7% | +3.3% | +2.1% | +0.3% | +1.4% | -3.5% |
| May 13 | Wells Fargo | Maintains | Overweight → Overweight | — | $36.93 | $37.22 | +0.8% | +0.2% | +6.4% | +1.2% | +2.4% | +2.4% |
| May 10 | BTIG | Maintains | Buy → Buy | — | $35.19 | $38.64 | +9.8% | +4.9% | +5.1% | +11.7% | +6.2% | +7.4% |
| Mar 26 | Stifel | Maintains | Buy → Buy | — | $38.48 | $40.65 | +5.6% | -2.3% | -3.8% | -1.4% | -3.8% | -10.8% |
| Mar 1 | Wells Fargo | Upgrade | Equal Weight → Overweight | — | $27.44 | $30.18 | +10.0% | +9.0% | +27.4% | +37.2% | +46.7% | +41.6% |
| Dec 18 | Stifel | Maintains | Buy → Buy | — | $15.50 | $16.83 | +8.6% | +2.0% | +5.8% | +0.3% | +11.1% | +17.2% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 1, 2026 | Turtle CameronDir/Off | Chief Executive Officer | Sell | 300 | $74.96 | $22K | 612,540 | -0.42% | +8.11% |
| May 1, 2026 | Turtle CameronDir/Off | Chief Executive Officer | Sell | 1,700 | $74.23 | $126K | 612,840 | -0.42% | +8.11% |
| May 1, 2026 | Turtle CameronDir/Off | Chief Executive Officer | Sell | 3,100 | $73.14 | $227K | 614,540 | -0.42% | +8.11% |
| May 1, 2026 | Turtle CameronDir/Off | Chief Executive Officer | Sell | 1,000 | $71.76 | $72K | 617,640 | -0.42% | +8.11% |
| May 1, 2026 | Turtle CameronDir/Off | Chief Executive Officer | Sell | 3,600 | $70.77 | $255K | 618,640 | -0.42% | +8.11% |
| May 1, 2026 | Turtle CameronDir/Off | Chief Executive Officer | Sell | 5,300 | $69.54 | $369K | 622,240 | -0.42% | +8.11% |
| May 1, 2026 | Burrows Scott LOff | Chief Financial Officer | Sell | 12,500 | $71.37 | $892K | 97,994 | -0.42% | +8.11% |
| May 1, 2026 | Sloan SheldonOff | Chief Medical Officer | Sell | 400 | $75.37 | $30K | — | -0.42% | +8.11% |
| May 1, 2026 | Sloan SheldonOff | Chief Medical Officer | Sell | 5,059 | $74.60 | $377K | 400 | -0.42% | +8.11% |
| May 1, 2026 | Sloan SheldonOff | Chief Medical Officer | Sell | 10,358 | $73.74 | $764K | 5,459 | -0.42% | +8.11% |
| May 1, 2026 | Sloan SheldonOff | Chief Medical Officer | Sell | 12,777 | $72.94 | $932K | 15,817 | -0.42% | +8.11% |
| May 1, 2026 | Sloan SheldonOff | Chief Medical Officer | Sell | 8,777 | $71.56 | $628K | 28,594 | -0.42% | +8.11% |
| May 1, 2026 | Sloan SheldonOff | Chief Medical Officer | Sell | 19,656 | $70.61 | $1.4M | 37,371 | -0.42% | +8.11% |
| May 1, 2026 | Sloan SheldonOff | Chief Medical Officer | Sell | 21,306 | $69.53 | $1.5M | 57,027 | -0.42% | +8.11% |
8-K · 2.02
!! High
Spyre Therapeutics, Inc. -- 8-K 2.02: Earnings Results
Spyre Therapeutics reported earnings results that are available in the furnished press release exhibit, providing investors with updates on the company's operational performance and financial condition.
May 5
8-K
Unknown — 8-K Filing
Syros Pharmaceuticals completed a securities offering in April 2026, likely diluting existing shareholders but providing capital for operations or acquisitions that investors should monitor for strategic impact.
Apr 16
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Syros' SKYLINE trial advancement delays proof-of-concept data to mid-2026 and Q3 2026, pushing potential catalysts back and increasing execution risk for investors awaiting clinical validation.
Apr 13
8-K
Unknown — 8-K Filing
Syros Pharmaceuticals suspended its ATM offering effective April 13, 2026, eliminating a key funding mechanism and signaling potential cash constraints or reduced near-term capital needs for the biotech company.
Apr 13
8-K
Spyre Therapeutics, Inc. -- 8-K Filing
Spyre Therapeutics announced full-year 2025 financial results and expects Phase 2 trial data that could validate its long-acting antibody platform for treating inflammatory bowel disease and rheumatic diseases, potentially driving clinical advancement.
Feb 19
Data updated apr 27, 2026 3:52am
· Source: massive.com